
Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Join expert James Song for an educational symposium dispelling myths surrounding the inflammatory pathways and clinical features of atopic dermatitis.
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.
The pathophysiology of chronic spontaneous urticaria (CSU) is complex and involves mast cell degranulation and elements of type 2 inflammation. Learn more about the role of mast cells, basophils, and type 2 inflammatory cells and cytokines involved in the pathophysiology of CSU.
Professors Netchiporouk and Hawkes discuss the clinical features and pathophysiology of CSU, at EADV 2025.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Professor Ulrike Raap reviews the pathophysiology of BP, highlighting the role of type 2 inflammation, in this video from EADV 2025

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

Explore the clinical presentation and pathophysiology of chronic spontaneous urticaria in this animated video. Learn about the complex mechanism of disease involving mast cell activation and the release of inflammatory mediators.
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.